All in the family: VEGF-B joins the ranks of proangiogenic cytokines

Circulation Research

Volumn 93, Issue 2, 2003, Pages 87-90

  Yoon, Young Sup ^b   Losordo, Douglas W ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b NONE

Author keywords

Akt; Angiogenesis; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor B; VEGFR 1

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOGENIC GROWTH FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 5; HYPOXIA INDUCIBLE ENDOTHELIAL CELL MITOGEN; MITOGENIC AGENT; NEUROPILIN 1; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; RECOMBINANT PROTEIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN B165; VASCULOTROPIN B167; VASCULOTROPIN B186; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANGIOGENESIS; ARTERY DISEASE; AUTOPHOSPHORYLATION; BINDING SITE; BLOOD VESSEL PERMEABILITY; CHROMOSOME 11Q; COLLATERAL CIRCULATION; EDITORIAL; GENE; GENE TRANSFER; HEART MUSCLE ISCHEMIA; HYPOXIA; ISCHEMIA; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIMB ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVASCULARIZATION; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; VASCULOTROPIN B GENE; VIRAL GENE THERAPY;

ANIMALS; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; HUMANS; MICE; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PERIPHERAL VASCULAR DISEASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0043269282     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000084992.10766.36     Document Type: Editorial

References (49)

1. Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.
2. Dormandy JA, Thomas PRS. What is the natural history of a critically ischemic patient with and without his leg? In: Greenhalgh RM, Jamieson CW, Nicolaides AN, eds. Limb Salvage and Amputation for Vascular Disease. 11th ed. Philadelphia, Pa: WB Saunders Co; 1988:11-26.
3. Dormandy JA, Loh A. Critical limb ischemia. In: Tooke JE, Lowe GDO, eds. A Textbook of Vascular Medicine. London, UK: Arnold; 1996:221-236.
4. European Working Group on Critical Leg Ischemia: second European consensus document on chronic critical leg ischemia. Circulation. 1991;84(suppl IV):IV-1-IV-26.
5. Losordo DW, Kawamoto A. Biological revascularization and the interventional molecular cardiologist: bypass for the next generation. Circulation. 2002;106:3002-3005.
6. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
7. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103:1231-1236.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-30.
9. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
10. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogcnesis. Am J Pathol. 1995;146:1029-1039.
11. Ferrara, N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocrinol Rev. 1997;18:4-25.
12. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol. 1999;237:41-57.
13. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211-220.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
15. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival as front-line therapy for advanced colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first line therapy in subjects with metastatic CRC. In: 39th Annual Meeting of the American Society of Clinical Oncology. Chicago, Ill;2003.
16. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest. 1994;93:662-670.
17. 121 improves lower-extremity endothelial function and flow reserve. Circulation. 2001;104:753-755.
18. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105:788-793.
19. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053-2058.
20. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002;105:1291-1297.
21. 165. Lancet. 1996;348:370-374.
22. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S, Symes JF. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28:964-973; discussion 73-75.
23. 165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
24. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105:2012-2018.
25. Silvestre J-S, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res. 2003;93:114-123.
26. Olofsson B, Pajusola K, Kaipainen A, vonEuler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576-2581.
27. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opht Biotechnol. 1999;10:528-535.
28. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-I and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95:11709-11714.
29. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;14:2475-2483.
30. Aase K, Lymboussaki A, Kaipainen A, Olofsson B, Alitalo K, Eriksson U. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn. 1999;215:12-25.
31. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
32. Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, Kay GF. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res. 2000;86:e29-e35.
33. Aase K, von Euler G, Li X, Ponten A, Thoren P, Cao R, Cao Y, Olofsson B, Gebre-Medhin S, Pekny M, Alitalo K, Betsholtz C, Eriksson U. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation. 2001;104:358-364.
34. Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol. 1999;212:307-322.
35. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745.
36. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, Eriksson U, Alitalo K. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem. 1999;274:21217-21222.
37. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 1999;126:3015-3025.
38. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998;95:9349-9354.
39. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 1996;15:4919-4927.
40. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269:25646-25654.
41. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothetial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583.
42. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.
43. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J. 2000;19:4064-4073.
44. Mara Y, Yamaguchi S, Shibuya M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene. 1998;16:2585-2595.
45. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002;90:e89-e93.
46. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem. 1998;273:22272-22278.
47. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development. 1995;121:4309-4318.
48. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
49. Fujio Y, Mano T, Takahashi T, Walsh K. Akt mediates the cell survival effects of vascular endothelial growth factor. Circulation. 1998;98(suppl I):I-463. Abstract.